Eli Lilly (LLY) made headlines with positive results from the Phase 3 BRUIN CLL-314 clinical trial for Jaypirca, marking a significant advancement in treatment options for chronic lymphocytic leukemia ...

Disclaimer - All information and content on this site are provided for informational and educational purposes only. They should NOT be used for the diagnosis or treatment of any health-related ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...